cultured renal cells which also related to protein stability, the generation of cAMP and phosphate transportation (26) .
In the present study, we identified a novel mutation of NHERF1, A190D, and explored its effects on cellular functions and interactions with signal molecules. The results indicate that this new NHERF1 mutation has important implication on the biological functions of cancer cells, in carcinogenesis and progression.
Materials and Methods
Cell lines and culture. Human breast cancer cell line MCF-7 and nonsmall cell lung cancer cell line SK-MES-1 were obtained from the European Collection for Animal Cell Cultures (Salisbury, Wiltshire, UK). MCF-7-riNHERF1 cell lines were constructed by stable transfection of MCF-7 cells with ribozyme targeted to NHERF1 thereby knocking down expression of NHREF1 (25) . HEK-293 and COS-7 cells were obtained from the American Type Culture Collection (Manassas, VA, USA). All cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% foetal bovine serum, 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco BRC, Paisley, UK) at 37˚C, with 5% CO 2 .
Human mammary specimens. Tissue samples were obtained from a total of 20 Chinese patients who had breast cancer. The tissues were collected immediately after mastectomy and snap-frozen in liquid nitrogen. The study received local Ethics Research Committee (approval number 2013SY15). None of the patients had any underlying medical condition and none was taking any medication. The genomic DNA from 20 frozen Chinese breast cancer tissues was extracted using the DNeasy kit (Qiagen, Hilden, Germany). All six exons of NHERF1 were amplified by PCR as described before (23) . The amplified sequences were analysed by single-strand conformation polymorphism also as previously described (27) .
Plasmids and cell transfection. The cDNA of wild-type NHERF1 (NHERF-WT) and NHERF1 A190D mutation were obtained by polymerase chain reaction (PCR) and cloned into pEASY™-M2 vector using pEASY-Blunt M2 Expression Kit (TransGen, Beijing, China) according to the manufacturer's instructions. Green fluorescent protein (GFP)-NHERF-WT and GFP-NHERF-A190D constructs were verified by DNA sequencing. Glutathione-S-transferase (GST)-NHERF1 construct was kindly provided by Dr. Jiale Dai (MD Anderson Cancer Center, Houston, TX, USA). GST-NHERF-A190D mutation construct was generated from the wild type using Fast MultiSite Mutagenesis System kit (TransGen) and verified by DNA sequencing.
Cell transfections were performed using Lipofectamine reagent (Invitrogen, Carlsbad, CA, USA) by following the manufacturer's instructions. The stably transfected cell lines were selected in selected culture medium containing 600 μg/ml G418. The expression of NHERF1 was verified by western blotting.
Cell proliferation assay. MCF-7-riNHERF1 and SK-MES-1 cells were seeded into 96-well plates in sextuplicate at a density of 2,000 cells per well. Plates were then incubated for 24, 48, 72 and 96 h before added CCK-8 reagent (Dojindo, Kumamoto, Japan), by following the manufacturer's instructions. The absorbance was measured at 450 nm using EnSpire label microplate reader (PerkinElmer, Waltham, MA, USA).
Wound-healing assay. MCF-7-riNHERF1 and SK-MES-1 cells were seeded into 6-well plates at a density of 5×10 5 cells per well and cultured until confluent. The layer of cells was scraped with a 5-gauge needle to create a wound. Images of the wound were recorded under microscopy at different time points (0, 6, 12 and 24 h). The width of wounds was evaluated by Image-Pro plus (National Institutes of Health, Bethesda, MD, USA).
Immunofluorescence staining. HEK-293 cells were seeded on a cover glass in 6-well plates and cultured overnight. The adherent cells were fixed with 4% paraformaldehyde and stained with 5 μg/ml Hochest 33258 (Zhongshan, China). Images were acquired under confocal microscopy (LAS AF-TCS SP5; Leica Microsystems Inc., Exton, PA, USA).
Nuclear and cytoplasmic protein extraction. The nuclear and cytoplasmic protein extracts were prepared using the Nucl-CytoMem Preparation kit (Applygen Technologies, China) according to the manufacturer's instructions. Briefly, the HEK-293 cells were digested and washed with cold phosphate-buffered saline. Then the cell pellets from centrifugation were incubated with cytoplasmic extraction and nuclear extraction reagent. The extractis were analysed by western blotting.
GST pull-down assays and western blotting. GST pull-down assays and western blotting were performed as described previously (28) . Antibody to NHERF1 was purchased from Becton Dickinson Company (Franklin Lake, NJ, USA), Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control (Santa Cruz Biotechnology, Santa Cruz, CA, USA). GFP was purchased from MBL life science (Nagoya, Japan). Histone deacetylase protein (HDAC) (Santa Cruz Biotechnology) was used as nuclear protein control, and α-tubulin was used as cytoplasmic protein control (Santa Cruz Biotechnology). YAP was purchased from Santa Cruz Biotechnology (Santa Cruz Biotechnology) and phospho-YAP (Ser127) was purchased from Cell Signalling Technology (Beverly, MA, USA). Horseradish peroxidase-conjugated secondary antibodies were obtained from ZSGB-BIO (Beijing, China).
Statistical analysis. Statistical analysis was performed using SPSS (IBM Corp, Armonk, New York, US). p-Value of less than 0.05 was considered to be statistically significant.
Results

NHERF1 A190D mutation identified in breast cancer.
A novel point-mutation, cytosine mutated to adenine at nucleotide position 569, was confirmed by DNA sequencing ( Figure 1A ). This point-mutation resulted in substitution in codon 190 (Ala/A-Asp/D), and is named here as A190D. The alanine 190 has been highly conserved in the PDZ2 domain of NHERF1 protein throughout evolution with other species as shown by the alignment of the NHERF1 protein sequence ( Figure 1B ). This suggests that the novel A190D mutation, not found in the 1000 Genomes Project database (http://browser.1000genomes.org/index.html), has the potential to affected the scaffold functions of the NHERF1 protein.
NHERF1 A190D mutation abolished the NHERF1 inhibition of cellular proliferation and migration. SK-MES-1 and MCF-7-riNHERF1 breast cancer cells were used in proliferation and migration assays because NHERF1 was poorly expressed in SK-MES-1 cells (23) . Our previous studies showed NHERF1 as a tumour-suppressor gene in breast cancer cells (25) . SK-MES-1 cells were stably transfected with NHERF1 WT or A190D mutation plasmid and expressions was detected by western blotting (Figure 2A ). The expression of WT and mutated NHERF1 protein in the respectively transfected cells was considerably increased compared to parental and vector control cells. The impact of NHERF1 A190D mutation on cellular proliferation and migration were subsequently tested with these cells. The rate of cell proliferation induced by NHERF1 A190D mutation increased by 35% (day 3) compared to WT NHERF1 ( Figure 2B ). Cellular migration in the wound-healing assay by cells carrying NHERF1 A190D mutation increased by 121% (12 h) compared to cells with WT NHERF1 (Figure 2C ).
MCF-7 cells expressed high levels of NHERF1. Using riNHERF1 plasmids, we established a stable NHERF1 knockdown cell line, MCF-7-riNHERF1, following transfection and selection. NHERF1-WT or NHERF1 A190D mutation plasmids were then stably transfected into the MCF-7-riNHERF1 cells, which resulted in expression of both WT and mutated NHERF1 proteins, respectively, as detected by western blotting (Figure 2A ). Using these new MCF7 sublines, it was found that cellular proliferation and migration increased 59% (day 3) and 120% (12 h), respectively induced by NHERF1 A190D mutation compared to WT NHERF1 ( Figure  2B and C). These results indicate that NHERF1 A190D mutation abrogated the inhibition of proliferation and migration by NHERF1 in SK-MES-1 and MCF-7-riNHERF1 cells.
Subcellular localization of mutated NHERF1 protein.
As reported before (29) , mutation of NHERF1 affects subcellular localization of its protein. We therefore also explored the effect of NHERF1 A190D mutation on localization by confocal assay. NHERF1-WT and NHERF-A190D were transfected into HEK-293 cells separately and detected by confocal microscopy. The fluorescence intensity in the nucleus increased, indicating a rise in nucleus localization of mutated NHERF1 protein, in clear contrast to the WT NHERF1 protein ( Figure 3A) . To further confirm this finding, the cytoplasmic and nuclear fractions were extracted from the respective cells and the levels of proteins in these fractions were further analysed by western blotting. Mutated NHERF1 protein was increased in the nucleus but decreased in the cytoplasm compared with WT NHERF1 protein using HDAC and α-tubulin as nuclear and cytoplasmic protein controls, respectively, in clear contrast to cells transfected with NHERF1-WT ( Figure 3B and C) . These data indicate Figure 
A: Novel mutation of Na + /H + exchanger regulatory factor (NHERF1) (A190D) identified in patients with breast cancer. A: The NHERF1 gene mutation (GCT to GAT) was identified by sequencing, which would cause a switch of codon 190 (Ala/A-Asp/D). B: The mutation site corresponded to a conserved basic residue in the post-synaptic density protein/Drosophila disc large tumour suppressor/zonula occludens 1 protein (PDZ)2 domain of NHERF1 protein.
NHERF1 A190D mutation results in increased translocation of NHERF1 protein to the nucleus compared to WT NHREF1. NHERF1 A190D mutation enhances NHERF1 association with YAP. It has been reported NHERF1 associates with YAP through its PDZ2 domain (8) . To determine the impact of NHERF1 A190D mutation on the interaction between NHERF1 and YAP, GST pull down assay was carried out. GST-NHERF1-WT and GST-NHERF1-A190D fusion proteins were purified and incubated with lysates of COS-7 cell expressing full-length YAP. It was very interesting to note that the level of YAP associated with mutated NHERF1 fusion protein increased by 59% compared with WT NHERF1 (Figure 4A and B) . The results indicate that YAP preferentially associated with mutated NHERF1 protein.
NHERF1 A190D mutation affects phosphorylation of YAP.
Phosphorylation of YAP is essential for its translocation into the nucleus in order for it to act as transcriptional coactivator. Therefore, we investigated the effect of mutated NHERF1 on interaction and phosphorylation of YAP. Overexpression of NHERF1 facilitated the phosphorylation of YAP. Phosphorylation of YAP was seen in both both NHERF1-A190D and NHERF1-WT transfected cells.
ANTICANCER RESEARCH 37: 67-74 (2017) 70 Figure 2. A: Na + /H + exchanger regulatory factor (NHERF1)-wild type (WT) and the NHERF1-A190D plasmids were stably transfected into SK-MES-1 cells and MCF-7 cells in which NHERF1 was stably knocked-down by riNHERF1 (MCF-7-riNHERF1). NHREF1 protein expression was then detected by western blotting. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as loading controls. NHERF1 A190D mutation abolished the inhibition of proliferation (B) and migration (C) induced by WT NHERF1 in SK-MES-1 cells and MCF-7-riNHERF1 cells. The results represent mean values±SD of three independent experiments. *p<0.05.
However, the phosphorylation of YAP in cells carrying NHERF1 A190D was significantly lower than that in cells with WT NHERF1 (Figure 5 ).
Discussion
The NHERF1 gene has been reported as a cancer-related gene in breast cancer. Up-regulation of NHERF1 in tumours has been associated with carcinogenesis, progression, and poor prognosis, indicating that NHERF1 is a potential oncoprotein in breast cancer and colon cancer (30, 31) contrast, NHERF1 has been to shown to act as anticancer gene in invasive breast carcinomas and breast cancer cells (21, 32) . These contrasting results may suggest that NHERF1 has diverse roles in breast cancer, possibly via different patterns of expression or mutations in different subtypes.
In our previous study, we found NHERF1 to act as an anticancer gene related to malignant phenotypes (25) . There have been several reports of missense mutations in NHERF1 PDZ domains in human breast cancer (7, 23, 25, 29) . In the present study, the coding region and the intron-exon junctions of NHERF1 were analysed in 20 human breast cancer tissues. A novel NHERF1 sequence variant (GCT to GAT), resulted in an amino acid change at residue 190 from alanine to aspartic acid, in the PDZ2 domain of NHERF1. We found overexpression of mutated NHERF1 abolished the suppression of proliferation and migration induced with WT NHERF1 in NHERF1 knock-down cells. This suggests WT NHERF1 has a tumour-suppressive role, while NHERF1 A190D mutation abolishes this tumour suppressive function of NHERF1 protein.
NHERF1 A190D mutation changed nonpolar alanine to acidic polar aspartic acid. This might lead to spatial structural changes of NHERF1 protein, resulting in alteration of subcellular location and biological activities in cancer cells.
NHERF1 is a typical scaffold protein and plays a role in cellular trafficking of other proteins (33) . It has been wellestablished that the trafficking proteins of different sublocalization may have different functions in the cells (34, 35) . In this study, we found NHERF1 A190D mutation resulted in an increase in the nuclear level of NHERF1, in a clear contrast to the WT NHERF1 protein. It has been shown that the PDZ1 domain of the NHERF1 protein is important in the importing the NHERF1 protein into the nucleus (29) . The reported mutation in the present study is located at the PDZ2 domain of NHERF1. Our findings also show the PDZ2 domain of NHERF1 has an influence in importing this to the nucleus.
YAP (also known as YAP1 or YAP65) can interact with NHERF1 (8) . YAP was first identified by its ability to associate with the SH3 domain of YES and SRC protein tyrosine kinases. When YAP is located in the nucleus, it acts as a transcriptional co-activator in cellular proliferation and other cancer-related malignant pathway (36) . In this study, we found NHERF1 A190D mutation also appears to affect YAP function. The phosphorylation of YAP at serine 127 residue promotes its binding to 14-3-3 and impairs the nuclear import of YAP (37) (38) (39) . NHERF1 A190D mutation led to a decrease in YAP phosphorylation. An increased binding affinity between mutated NHERF1 and YAP would lead to less phosphorylation of YAP, as shown in the present study. Therefore, the association between 14-3-3 protein and the phosphorylated serine residue of YAP would also decrease, facilitating YAP translocation into the nucleus and increasing its transcriptional activity. The novel influence of NHERF1 point mutation on cellular proliferation and migration suggests the regulation of PDZ scaffold protein would have great impact on cancer cells.
Here we found a novel NHERF1 A190D mutation which rescued cells from inhibited proliferation and migration by WT NHERF1, and affected localisation of NHERF1 and YAP proteins, both of which may have profound effects on cancer cell behaviour.
